— DexCom, Inc. (NASDAQ: DXCM) reported its fourth-quarter 2019 adjusted earnings of $1.15 per share versus $0.74 per share expected.
— Total revenue grew by 37% to $462.8 million versus $442.38 million expected. This is driven by volume growth, strong new patient additions as well as an increase in awareness of real-time CGM.
— The US revenue increased by 34% year-over-year and the international revenue jumped by 52%.
— Revenue from the sensor increased by 42% for the fourth quarter. Transmitter revenue jumped by 46% while receiver revenue plunged by 35%.
— Looking ahead into the full year 2020, the company reaffirmed revenue outlook in the range of $1.725-1.775 billion. This is in line with the consensus view of $1.77 billion.
— The revenue outlook is driven by strong growth in sensor volumes, continued international expansion, shifting channel mix and overall market dynamics.
— The gross margin is still expected to be about 64% and the adjusted operating margin is predicted to be about 13%. The adjusted EBITDA margin outlook is about 23%.
Most Popular
Adobe Inc. (ADBE) Stock: Should you invest in this recession-proof tech firm?
Adobe, Inc. (NASDAQ: ADBE) has been dominating the design software space for quite some time, all along staying resilient to macroeconomic fluctuations and market headwinds. The company’s cloud-based applications, offered
Brilliant Earth IPO: Here are a few points to note about this jewelry company that goes public next week
Jewelry has always played a significant role in people’s lives. As life begins to go back to normal after the pandemic and people start attending social events, they are looking
Kontrol Technologies CEO Paul Ghezzi: Our focus is on reinvesting for growth
Tell us about BioCloud, how it’s different from any alternate existing products, and your distribution model. BioCloud exists as a part of Kontrol Technologies and is an innovation within our
